Profile data is unavailable for this security.
About the company
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
- Revenue in USD (TTM)4.43bn
- Net income in USD-113.90m
- Incorporated2013
- Employees9.14k
- LocationPerrigo Company PLCThe Sharp BuildingHogan Place, Dublin 2DUBLIN D02 TY74IrelandIRL
- Phone+353 17094000
- Websitehttps://www.perrigo.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals Inc | 712.89m | 166.52m | 2.42bn | 1.76k | 15.86 | 3.42 | 11.04 | 3.40 | 3.14 | 3.14 | 13.45 | 14.57 | 0.4968 | 2.85 | 6.04 | 404,821.70 | 11.71 | 9.42 | 13.54 | 11.56 | 54.68 | 47.83 | 23.56 | 15.23 | 2.63 | 7.42 | 0.4515 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Catalyst Pharmaceuticals Inc | 434.48m | 68.15m | 2.42bn | 167.00 | 38.30 | 3.98 | 23.15 | 5.58 | 0.5335 | 0.5335 | 3.71 | 5.14 | 0.7554 | 4.03 | 8.69 | 2,601,647.00 | 11.85 | 25.42 | 13.56 | 29.81 | 86.67 | 85.63 | 15.69 | 30.87 | 4.94 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Amneal Pharmaceuticals Inc | 2.60bn | -174.62m | 2.70bn | 7.70k | -- | -- | 29.29 | 1.04 | -0.6224 | -0.6224 | 10.09 | -0.1857 | 0.7206 | 3.00 | 3.60 | 337,401.60 | -3.69 | -4.80 | -4.93 | -5.93 | 35.04 | 34.76 | -5.13 | -9.00 | 0.8165 | 1.24 | 1.00 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Twist Bioscience Corp | 295.21m | -220.31m | 2.75bn | 919.00 | -- | 5.60 | -- | 9.33 | -3.81 | -3.81 | 5.12 | 8.39 | 0.4076 | 5.42 | 8.56 | 321,229.60 | -30.42 | -30.50 | -33.85 | -33.84 | 40.53 | 36.02 | -74.63 | -113.33 | 4.52 | -- | 0.00 | -- | 20.41 | 57.33 | 6.08 | -- | 49.76 | -- |
| Prestige Consumer Healthcare Inc | 1.11bn | 205.13m | 3.64bn | 570.00 | 17.99 | 2.17 | 15.42 | 3.27 | 4.09 | 4.09 | 22.18 | 33.92 | 0.3346 | 3.09 | 6.75 | 1,952,965.00 | 6.17 | 3.69 | 6.42 | 3.84 | 55.32 | 56.79 | 18.43 | 12.19 | 1.90 | 5.26 | 0.3939 | 0.00 | -0.21 | 2.89 | 354.34 | -- | -1.84 | -- |
| Perrigo Company PLC | 4.43bn | -113.90m | 3.84bn | 9.14k | -- | 0.845 | 16.98 | 0.8675 | -0.833 | -0.9106 | 32.37 | 33.32 | 0.4146 | 2.48 | 5.78 | 484,496.70 | -1.07 | -0.1148 | -1.21 | -0.1315 | 35.93 | 35.28 | -2.57 | -0.2985 | 1.24 | 1.15 | 0.4717 | -- | 4.58 | -0.3238 | 96.64 | -- | -5.95 | 7.52 |
| Apellis Pharmaceuticals Inc | 628.79m | -332.89m | 4.34bn | 702.00 | -- | 16.40 | -- | 6.90 | -2.74 | -2.74 | 5.15 | 2.17 | 0.6910 | 0.669 | 3.03 | 895,706.60 | -36.58 | -73.88 | -45.11 | -90.03 | 86.38 | -- | -52.94 | -326.49 | 4.18 | -17.87 | 0.6337 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Axsome Therapeutics Inc | 291.49m | -308.55m | 4.39bn | 545.00 | -- | 42.54 | -- | 15.07 | -6.51 | -6.51 | 6.15 | 2.15 | 0.5026 | 2.31 | 3.11 | 534,842.20 | -53.20 | -64.55 | -71.90 | -82.23 | 90.30 | -- | -105.85 | -227.05 | 2.40 | -79.61 | 0.6409 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Corcept Therapeutics Incorporated | 569.61m | 125.98m | 4.42bn | 352.00 | 37.18 | 7.40 | 34.80 | 7.75 | 1.14 | 1.14 | 5.14 | 5.71 | 0.9193 | 1.12 | 13.19 | 1,618,210.00 | 20.33 | 21.17 | 24.10 | 23.85 | 98.49 | 98.52 | 22.12 | 27.23 | 5.48 | -- | 0.00 | 0.00 | 20.04 | 13.93 | 4.66 | 7.08 | -14.15 | -- |
| ADMA Biologics Inc | 330.24m | 34.79m | 4.50bn | 624.00 | 137.40 | 23.91 | 104.36 | 13.64 | 0.1406 | 0.1406 | 1.41 | 0.8079 | 0.9181 | 1.04 | 9.88 | 529,237.60 | 9.67 | -24.80 | 10.99 | -28.00 | 46.12 | 17.40 | 10.53 | -51.31 | 2.80 | 4.59 | 0.4105 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| BridgeBio Pharma Inc | 219.12m | -453.82m | 4.88bn | 550.00 | -- | -- | -- | 22.28 | -2.64 | -2.64 | 1.24 | -5.81 | 0.3376 | -- | -- | 398,407.30 | -71.11 | -72.44 | -89.59 | -89.72 | 98.91 | 94.41 | -210.62 | -1,225.66 | -- | -9.63 | 2.70 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Organon & Co | 6.35bn | 1.00bn | 5.14bn | 10.00k | 5.14 | 35.71 | 4.11 | 0.8102 | 3.89 | 3.89 | 24.65 | 0.5593 | 0.5487 | 2.11 | 3.86 | 634,600.00 | 8.65 | 16.53 | 11.12 | 20.97 | 58.59 | 65.12 | 15.76 | 26.79 | 1.17 | 2.37 | 0.9836 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Avidity Biosciences Inc | 10.60m | -252.45m | 5.20bn | 253.00 | -- | 3.99 | -- | 490.92 | -2.95 | -2.95 | 0.1231 | 11.17 | 0.0108 | -- | 17.92 | 41,893.28 | -25.78 | -31.61 | -27.61 | -34.45 | -- | -- | -2,381.82 | -1,540.50 | -- | -- | 0.00 | -- | 3.64 | 90.71 | -21.97 | -- | 143.89 | -- |
Data as of Sep 19 2024. Currency figures normalised to Perrigo Company PLC's reporting currency: US Dollar USD
43.32%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 14.59m | 10.70% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 11.66m | 8.55% |
| Dimensional Fund Advisors LPas of 30 Jun 2024 | 6.85m | 5.03% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 6.83m | 5.01% |
| DePrince, Race & Zollo, Inc.as of 30 Jun 2024 | 3.88m | 2.85% |
| Davenport & Co. LLCas of 30 Jun 2024 | 3.56m | 2.61% |
| Cooke & Bieler LPas of 30 Jun 2024 | 3.50m | 2.57% |
| Thompson, Siegel & Walmsley LLCas of 30 Jun 2024 | 3.15m | 2.31% |
| JOHCM (USA), Inc.as of 30 Jun 2024 | 2.66m | 1.95% |
| Philosophy Capital Management LLCas of 30 Jun 2024 | 2.40m | 1.76% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
